Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386815898> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4386815898 abstract "Many systemic chemotherapies, including immune checkpoint inhibitors (ICI), are now available for the treatment of advanced hepatocellular carcinoma. On the other hand, it is often difficult to continue administration of angiogenesis inhibitors in these patients due to various side effects. In the two cases described in this paper, following the introduction of combination therapy with atezolizumab plus bevacizumab (Atezo/Bev), it was difficult to continue bevacizumab treatment due to side effects, such as proteinuria and fluid retention, with disease control in the two patients being ultimately poor. However, both patients experienced treatment success after switching Atezo/Bev to a regimen that included durvalumab, an anti-programmed cell death ligand 1 antibody (anti-PD-L1 antibody) similar to atezolizumab, plus tremelimumab, an anti-cytotoxic T lymphocyte-associated antigen 4 antibody (anti-CTLA-4 antibody) in situations where the continuation of bevacizumab was difficult. The efficacy of subsequent drug sequencing from ICI to another ICI after atezolizumab plus bevacizumab, which is the standard first-line treatment in advanced hepatocellular carcinoma, has not yet been established. We consider that the two cases described in this paper provide valuable information worthy of the report." @default.
- W4386815898 created "2023-09-18" @default.
- W4386815898 creator A5014470642 @default.
- W4386815898 creator A5026182073 @default.
- W4386815898 creator A5044932403 @default.
- W4386815898 creator A5053329267 @default.
- W4386815898 creator A5084522512 @default.
- W4386815898 date "2023-09-16" @default.
- W4386815898 modified "2023-10-15" @default.
- W4386815898 title "Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal" @default.
- W4386815898 cites W2019607817 @default.
- W4386815898 cites W2056476092 @default.
- W4386815898 cites W3025022288 @default.
- W4386815898 cites W3096245719 @default.
- W4386815898 cites W3128927131 @default.
- W4386815898 cites W3154322879 @default.
- W4386815898 cites W3159001445 @default.
- W4386815898 cites W3213277274 @default.
- W4386815898 cites W4200547311 @default.
- W4386815898 cites W4213096024 @default.
- W4386815898 cites W4225146220 @default.
- W4386815898 cites W4281645619 @default.
- W4386815898 cites W4286493879 @default.
- W4386815898 cites W4307645826 @default.
- W4386815898 cites W4308401414 @default.
- W4386815898 cites W4317892038 @default.
- W4386815898 cites W4382726175 @default.
- W4386815898 cites W4385308457 @default.
- W4386815898 doi "https://doi.org/10.7759/cureus.45385" @default.
- W4386815898 hasPublicationYear "2023" @default.
- W4386815898 type Work @default.
- W4386815898 citedByCount "0" @default.
- W4386815898 crossrefType "journal-article" @default.
- W4386815898 hasAuthorship W4386815898A5014470642 @default.
- W4386815898 hasAuthorship W4386815898A5026182073 @default.
- W4386815898 hasAuthorship W4386815898A5044932403 @default.
- W4386815898 hasAuthorship W4386815898A5053329267 @default.
- W4386815898 hasAuthorship W4386815898A5084522512 @default.
- W4386815898 hasBestOaLocation W43868158981 @default.
- W4386815898 hasConcept C121608353 @default.
- W4386815898 hasConcept C126322002 @default.
- W4386815898 hasConcept C143998085 @default.
- W4386815898 hasConcept C2775949291 @default.
- W4386815898 hasConcept C2776694085 @default.
- W4386815898 hasConcept C2777701055 @default.
- W4386815898 hasConcept C2777742743 @default.
- W4386815898 hasConcept C2777802072 @default.
- W4386815898 hasConcept C2778650287 @default.
- W4386815898 hasConcept C2780030458 @default.
- W4386815898 hasConcept C2781413609 @default.
- W4386815898 hasConcept C2781433595 @default.
- W4386815898 hasConcept C71924100 @default.
- W4386815898 hasConceptScore W4386815898C121608353 @default.
- W4386815898 hasConceptScore W4386815898C126322002 @default.
- W4386815898 hasConceptScore W4386815898C143998085 @default.
- W4386815898 hasConceptScore W4386815898C2775949291 @default.
- W4386815898 hasConceptScore W4386815898C2776694085 @default.
- W4386815898 hasConceptScore W4386815898C2777701055 @default.
- W4386815898 hasConceptScore W4386815898C2777742743 @default.
- W4386815898 hasConceptScore W4386815898C2777802072 @default.
- W4386815898 hasConceptScore W4386815898C2778650287 @default.
- W4386815898 hasConceptScore W4386815898C2780030458 @default.
- W4386815898 hasConceptScore W4386815898C2781413609 @default.
- W4386815898 hasConceptScore W4386815898C2781433595 @default.
- W4386815898 hasConceptScore W4386815898C71924100 @default.
- W4386815898 hasLocation W43868158981 @default.
- W4386815898 hasOpenAccess W4386815898 @default.
- W4386815898 hasPrimaryLocation W43868158981 @default.
- W4386815898 hasRelatedWork W1781719481 @default.
- W4386815898 hasRelatedWork W2285109017 @default.
- W4386815898 hasRelatedWork W2415761526 @default.
- W4386815898 hasRelatedWork W2518718160 @default.
- W4386815898 hasRelatedWork W2800311363 @default.
- W4386815898 hasRelatedWork W3000961096 @default.
- W4386815898 hasRelatedWork W3036371943 @default.
- W4386815898 hasRelatedWork W3104083510 @default.
- W4386815898 hasRelatedWork W3119432592 @default.
- W4386815898 hasRelatedWork W3170189973 @default.
- W4386815898 isParatext "false" @default.
- W4386815898 isRetracted "false" @default.
- W4386815898 workType "article" @default.